title: Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance.
abstract: Insulin resistance and type 2 diabetes are associated with elevated circulating levels of insulin, nonesterified fatty acids (NEFAs), and lipoprotein remnants. Extracellular matrix proteoglycan (PG) alterations are also common in macro- and microvascular complications of type 2 diabetes. In liver, extracellular heparan sulfate (HS) PGs contribute to the uptake of triglyceride-rich lipoprotein remnants. We found that HepG2 cells cultured with 10 or 50 nmol/l insulin or 300 micromol/l albumin-bound linoleic acid changed their PG secretion. The glycosaminoglycans (GAGs) of the secreted PGs from insulin-treated HepG2 cells were enriched in chondroitin sulfate (CS) PGs. In contrast, cells exposed to linoleic acid secreted PGs with decreased content of CS. Insulin caused a moderate increase in mRNA for versican (secreted CS PG), whereas linoleic acid markedly decreased mRNA for versican in HepG2 cells, as did the peroxisomal proliferator-activated receptor-alpha agonist bezafibrate. The effects of insulin or linoleic acid on syndecan 1, a cell surface HS PG, were similar to those on versican, but less pronounced. The livers of obese Zucker fa/fa rats, which are insulin-resistant and have high levels of insulin, NEFAs, and triglyceride-rich remnants, showed increased expression of CS PGs when compared with lean littermates. These changes in PG composition decreased the affinity of remnant beta-VLDL particles to PGs isolated from insulin-treated HepG2 cells and obese rat livers. The results indicated that insulin and NEFAs modulate the expression of PGs in hepatic cells. We speculate that in vivo this exchange of CS for HS may reduce the clearance of remnant beta-VLDLs and contribute to the dyslipidemia of insulin resistance.
authors.affiliation: Wallenberg Laboratory for Cardiovascular Research, Göteborg University, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: U
authors.initials: U
authors.lastname: Olsson
authors.forename: A C
authors.initials: AC
authors.lastname: Egnell
authors.forename: M R
authors.initials: MR
authors.lastname: Lee
authors.forename: G O
authors.initials: GO
authors.lastname: Lundén
authors.forename: M
authors.initials: M
authors.lastname: Lorentzon
authors.forename: M
authors.initials: M
authors.lastname: Salmivirta
authors.forename: G
authors.initials: G
authors.lastname: Bondjers
authors.forename: G
authors.initials: G
authors.lastname: Camejo
mesh_terms: D000818:Animals; D002460:Cell Line; D005109:Extracellular Matrix / Q000378:metabolism; D005227:Fatty Acids / Q000494:pharmacology*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D007328:Insulin / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology*; D019787:Linoleic Acid / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000097:blood; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D009765:Obesity / Q000235:genetics / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D011924:Rats, Zucker / Q000378:metabolism; D013851:Thinness
chemical_list: D005227:Fatty Acids; D007328:Insulin; D008079:Lipoproteins, VLDL; D011509:Proteoglycans; D019787:Linoleic Acid